ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1050

Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US

Hassan Ghomrawi1, Alvin Mushlin2, Raymond Kang3, Samprit Banerjee2, Jasvinder A. Singh4, Leena Sharma5, Tuhina Neogi6, Michael C. Nevitt7 and Daniel Riddle8, 1Surgery and Pediatrics/Center for Healthcare Studies, Feinberg School of Medicine of Northwestern University, Chicago, IL, 2Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, 3Center for Healthcare Studies, Feinberg School of Medicine of Northwestern University, Chicago, IL, 4Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 7Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 8Virginia Commonwealth University, Richmond, VA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Health Care, Knee, osteoarthritis and surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The elective nature of knee replacement (KR) creates difficult decisions and the potential for both overuse and underuse. We examined the temporal relationship between needing a KR and actually undergoing one to determine the rates and investigate predicotrs of overuse and underuse.

Methods: We pooled longitudinal data from the Osteoarthritis Initiative (OAI) and the Multicenter Osteoarthritis (MOST) Study to estimate KR overuse and underuse.  These cohorts closely followed 8,002 participants with or at risk of knee OA over multiple years and collected demographic, patient-reported, radiographic, and clinical exam information. To determine need for KR, we longitudinally applied the modified and validated Escobar KR appropriateness criteria (AC) to classify participants as either appropriate or inappropriate for KR (Table 1). Examining the temporal relationship between appropriateness status and KR utilization, we classified participants into: 1) appropriate and had KR (appropriate use), 2) appropriate but did not have KR (potential underuse), and 3) inappropriate but had KR (potential overuse). We used multinomial logistic regression to estimate the association between overuse and underuse and age, sex, race, educational status, obesity categories, CESD depression score>16, SF-12 PCS, Charlson comorbidity score, and living alone. We repeated our analyses by dividing potential underusers into those with and without extreme pain (an indicator of necessity and a likely substantial benefit from KR).

Table 1: Elements of the modified Escobar appropriateness criteria for KR*

Factor

Levels

Age

1-<55 years

2-55-65 years

3->65 years

Knee Stability

1-Preserved mobility and stable joint (<5 degrees flexion contracture and normal or minor medial or lateral gapping in the 20 degrees flexed knee)

2-Limited mobility and/or unstable joint (>=5 degrees flexion contracture and/or moderate or severe medial or lateral gapping in the 20 degrees flexed knee)

Compartments involved

1-Uni-compartmental

2-Bi/ tri-compartmental

Radiographic findings

1-Slight (KL grade <=3)

2-Moderate or severe (KL grade = 4)

Symptomatology

1-Slight (mild overall functional loss and function-related pain [e.g. up to half of WOMAC pain and physical scale items scored from 0 to 11])

2-Moderate (moderate overall functional loss and function-related pain [e.g. up to half of WOMAC pain and physical scale items scored from 12 to 22])

3-Intense (intense overall functional loss and function-related pain [e.g. up to half of WOMAC pain and physical scale items scored from 23 to 33]) or

4-Severe (severe overall functional loss and function-related pain [e.g. up to half of WOMAC pain and physical scale items scored from >=34])

*16 combination of factors, depending on levels involved, determined whether person was appropriate or inappropriate for surgery. Example: for a 54-year-old patient with KL=4 and moderate symptoms TKR is inappropriate; however, if the symptoms are intense or severe TKR becomes appropriate

.

Results: 3,449 of 8,002 participants fell into one of the 3 groups, with 843 (24.4%) classified as appropriate users, 2256 (65.4%) as potential underusers, and 350 (10.1%) as potential overusers. Of potential underusers, 988 (43.8%) were deemed likely to receive substantial benefit.  Compared to appropriate use, the odds of underuse were greater in blacks (OR=2.9, 95% CI [2.3, 3.8]). The odds of overuse increased with postgraduate degree, higher SF-12 PCS score, living alone, and decreased with being overweight or obese, having depressive symptoms, and having comorbidities.  Distinguishing necessary from not necessary but appropriate in the underuser group increased racial disparities in KR underuse (blacks OR=4.9, 95% CI[3.8, 6.5]), without significantly affecting findings related to the other predictors.

Conclusion: We found a substantial proportion of patients either overuse or underuse KR. For the underusers, almost 50% would likely receive substantial benefit if they underwent KR and of these, African Americans are at greatest risk for underuse. Overuse appears to be less of a issue but still occurs approximately 10% of the time. Future work needs to focus on ways of  reducing rates of overuse and underuse of KR given the substantial costs and consequences of the procedure.  


Disclosure: H. Ghomrawi, NIH, QNRF, 2,Haman Medical Corporation, NIH, 5; A. Mushlin, None; R. Kang, None; S. Banerjee, None; J. A. Singh, Takeda and Savient, 2,Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology, 5,JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity., 9,JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies., 9,JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis., 9,JAS is a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee., 9,JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee., 9; L. Sharma, None; T. Neogi, None; M. C. Nevitt, None; D. Riddle, None.

To cite this abstract in AMA style:

Ghomrawi H, Mushlin A, Kang R, Banerjee S, Singh JA, Sharma L, Neogi T, Nevitt MC, Riddle D. Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-predictors-of-knee-replacement-overuse-and-underuse-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-predictors-of-knee-replacement-overuse-and-underuse-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology